Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02348489 · ClinicalTrials.gov registry record · Phase 3
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
A Phase 3 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 815
- Enrollment target
NCT02348489: Completed Phase 3 study, sponsored by Astex Pharmaceuticals.
NCT02348489 is a Phase 3 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 815 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02348489, a Phase 3 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 815 participants
- Enrollment target
Study Summary
To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.
Primary Outcome
Number of participants with a best response of CR assessed based on International Working Group 2003 acute myeloid leukemia (AML) response criteria by a blinded independent pathologist.
Interventions
- DRUG SGI-110 (guadecitabine)
- DRUG Treatment Choice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 815 participants |
| Start Date | 2015-03-19 |
| Est. Completion | 2019-06-17 |
| Phase | Phase 3 |
What the finished NCT02348489 record still lists
NCT02348489 is an interventional study that assigns participants to a tested intervention. The registered 815 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which SGI-110 (guadecitabine) is the first listed.
NCT02348489 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02348489 about?
NCT02348489 is a clinical study titled "SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction". To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.
What is the current status of trial NCT02348489?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 815 participants. The study started on 2015-03-19. Estimated completion is 2019-06-17.
What interventions are being tested in trial NCT02348489?
The interventions under investigation include: SGI-110 (guadecitabine) (DRUG), Treatment Choice (DRUG).
Who is sponsoring clinical trial NCT02348489?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02348489's enrollment target sits among peer trials
815 406th of 2000 higher than 1,594 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI